AstraZeneca and Bristol Myers Squibb Deny Merger Talks
On Wednesday, a high-ranking insider informed Reuters that there have been no merger discussions between AstraZeneca and Bristol Myers Squibb, nor are any talks currently underway. This statement seeks to address the ongoing market speculation regarding a possible union of the two pharmaceutical powerhouses. The anonymous source emphasized that no negotiations for a merger have taken place. While neither company has released an official comment, the insider's statements carry weight. This development is crucial for investors and the pharmaceutical sector, as a merger of this magnitude would significantly impact the industry. Nonetheless, the denial indicates that such a deal is not being considered. Quartz reported this information, referencing Reuters.
Key facts
- AstraZeneca and Bristol Myers Squibb never held merger discussions.
- The companies are not in talks now.
- A senior source close to the matter told Reuters on Wednesday.
- The denial comes amid market speculation.
- The source spoke on condition of anonymity.
- Neither company has issued an official statement.
- The report was published by Quartz, citing Reuters.
Entities
Institutions
- AstraZeneca
- Bristol Myers Squibb
- Reuters
- Quartz
Sources
- Quartz —